We demonstrate the superiority of circulating VEGF from plasma over serum of therapy-naïve HNSCC patients as a potential biomarker and further validate its potential as an independent predictor (Pi) of outcome in an independent cohort. The gene discussed is VEGFA; the disease is head and neck squamous cell carcinoma.